Shopping Cart
Remove All
Your shopping cart is currently empty
MS479 is a BRD4 PROTAC degrader that binds with high affinity to BRD4-BD2 and GLP (BRD4-BD2: Kd = 200 nM; GLP: Kd = 306 nM). It effectively reduces the protein levels of BRD4 short isoforms. By directly binding to its substrate GLP, MS479 recruits the E3 ligase SPOP as a bridging protein. Additionally, MS479 can be utilized to inhibit the proliferation of colorectal cancer cells.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | Backorder | Backorder | |
| 50 mg | Inquiry | Backorder | Backorder |
| Description | MS479 is a BRD4 PROTAC degrader that binds with high affinity to BRD4-BD2 and GLP (BRD4-BD2: Kd = 200 nM; GLP: Kd = 306 nM). It effectively reduces the protein levels of BRD4 short isoforms. By directly binding to its substrate GLP, MS479 recruits the E3 ligase SPOP as a bridging protein. Additionally, MS479 can be utilized to inhibit the proliferation of colorectal cancer cells. |
| In vitro | MS479 (Compound 9) exhibits optimal degradation of BRD4 (S) in the HT29 cell line at concentrations between 0.5-5 μM over 24 hours, with degradation rates exceeding 50% at 5 μM. However, its effect on BRD4 (L) protein levels is relatively weaker, achieving around 50% degradation at 10 μM (DC 50 = 13.2 μM) over the same period. MS479 regulates BRD4 protein levels in HT29 cells via post-translational mechanisms within the range of 1-10 μM. A concentration of 5 μM over 24 hours suggests BRD4 (S) degradation relies on the participation of BRD4, GLP, SPOP, and UPS in HT29 cells. Additionally, MS479 demonstrates significant, concentration-dependent antiproliferative effects in HT29 cells (GI 50 = 4.5 μM) over 72 hours, while showing no cytotoxicity in normal cells. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.